

William E Boden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1026983/publications.pdf>

Version: 2024-02-01

102
papers

11,387
citations

201674

27
h-index

39675

94
g-index

105
all docs

105
docs citations

105
times ranked

10102
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimal Medical Therapy with or without PCI for Stable Coronary Disease. New England Journal of Medicine, 2007, 356, 1503-1516.	27.0	4,022
2	Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New England Journal of Medicine, 2011, 365, 2255-2267.	27.0	2,523
3	Initial Invasive or Conservative Strategy for Stable Coronary Disease. New England Journal of Medicine, 2020, 382, 1395-1407.	27.0	1,508
4	Management of Coronary Disease in Patients with Advanced Kidney Disease. New England Journal of Medicine, 2020, 382, 1608-1618.	27.0	310
5	Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. New England Journal of Medicine, 2020, 382, 1408-1419.	27.0	287
6	Percutaneous Coronary Intervention Outcomes in Patients With Stable Obstructive Coronary Artery Disease and Myocardial Ischemia. JAMA Internal Medicine, 2014, 174, 232.	5.1	245
7	Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. New England Journal of Medicine, 2015, 373, 1937-1946.	27.0	225
8	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. American Heart Journal, 2018, 201, 124-135.	2.7	202
9	Relationship of Lipoproteins to Cardiovascular Events. Journal of the American College of Cardiology, 2013, 62, 1580-1584.	2.8	156
10	Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. Journal of the American College of Cardiology, 2018, 72, 330-343.	2.8	152
11	Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nature Genetics, 2019, 51, 1574-1579.	21.4	152
12	Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. EClinicalMedicine, 2021, 38, 100997.	7.1	121
13	Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a Review. Kidney International, 2017, 91, 797-807.	5.2	102
14	Intensive Multifactorial Intervention for Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2010, 55, 1348-1358.	2.8	96
15	β ₂ -Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 872-881.	2.2	84
16	Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial. American Heart Journal, 2006, 151, 1173-1179.	2.7	82
17	The Evolving Pattern of Symptomatic Coronary Artery Disease in the United States and Canada: Baseline Characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial. American Journal of Cardiology, 2007, 99, 208-212.	1.6	70
18	Optimal Medical Therapy With or Without Percutaneous Coronary Intervention in Older Patients With Stable Coronary Disease. Journal of the American College of Cardiology, 2009, 54, 1303-1308.	2.8	54

#	ARTICLE	IF	CITATIONS
19	Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. <i>European Heart Journal</i> , 2020, 41, 2304-2312.	2.2	54
20	The Therapeutic Role of Niacin in Dyslipidemia Management. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 141-158.	2.0	52
21	Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 985-995.	2.8	52
22	Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2252-2266.	2.8	52
23	Physical Activity and Structured Exercise for Patients With Stable Ischemic Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 143.	7.4	48
24	Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2297-2305.	2.8	42
25	Subcutaneous Implantable Cardioverter Defibrillator for Dialysis Patients: A Strategy to Reduce Central Vein Stenoses and Infections. <i>American Journal of Kidney Diseases</i> , 2015, 66, 154-158.	1.9	33
26	Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial. <i>American Heart Journal</i> , 2016, 173, 108-117.	2.7	30
27	Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease. <i>American Heart Journal</i> , 2020, 224, 65-76.	2.7	30
28	Nitrates as an Integral Part of Optimal Medical Therapy and Cardiac Rehabilitation for Stable Angina: Review of Current Concepts and Therapeutics. <i>Clinical Cardiology</i> , 2012, 35, 263-271.	1.8	28
29	Role of short-acting nitroglycerin in the management of ischemic heart disease. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4793.	4.3	28
30	HDL Hypothesis: Where Do We Stand Now?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 398.	4.8	24
31	External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction. <i>Atherosclerosis</i> , 2018, 272, 80-86.	0.8	24
32	Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2049-2058.	2.8	24
33	Outcomes of Participants With Diabetes in the ISCHEMIA Trials. <i>Circulation</i> , 2021, 144, 1380-1395.	1.6	24
34	Effect of Coronary Anatomy and Myocardial Ischemia on Long-Term Survival in Patients with Stable Ischemic Heart Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005079.	2.2	22
35	DTCA for PTCA â€” Crossing the Line in Consumer Health Education?. <i>New England Journal of Medicine</i> , 2008, 358, 2197-2200.	27.0	18
36	Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2197-2207.	2.8	18

#	ARTICLE	IF	CITATIONS
37	Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. <i>Heart</i> , 2021, 107, 1739-1747.	2.9	18
38	Mounting Evidence for Lack of PCI Benefit in Stable Ischemic Heart Disease:What More Will It Take to Turn the Tide of Treatment?. <i>Archives of Internal Medicine</i> , 2012, 172, 319.	3.8	17
39	Exercise as a Therapeutic Intervention in Patients with Stable Ischemic Heart Disease: An Underfilled Prescription. <i>American Journal of Medicine</i> , 2014, 127, 905-911.	1.5	17
40	Temporal Trends in Unstable Angina Diagnosis Codes for Outpatient Percutaneous Coronary Interventions. <i>JAMA Internal Medicine</i> , 2019, 179, 259.	5.1	17
41	Contemporary Approach to the Diagnosis and Management of Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Progress in Cardiovascular Diseases</i> , 2008, 50, 311-351.	3.1	16
42	Antianginal Therapy for Stable Ischemic Heart Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2017, 22, 499-510.	2.0	15
43	Death and Myocardial Infarction Following Initial Revascularization Versus Optimal Medical Therapy in Chronic Coronary Syndromes With Myocardial Ischemia: A Systematic Review and Meta-Analysis of Contemporary Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2021, 10, e019114.	3.7	15
44	Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial. <i>American Heart Journal</i> , 2022, 248, 72-83.	2.7	15
45	Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. <i>Future Cardiology</i> , 2021, 17, 155-174.	1.2	14
46	Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial. <i>Journal of the American College of Cardiology</i> , 2022, 79, 651-661.	2.8	14
47	Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial. <i>European Heart Journal</i> , 2022, 43, 148-149.	2.2	13
48	Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. <i>JAMA Network Open</i> , 2022, 5, e2148172.	5.9	11
49	Reexamining the Efficacy and Value of Percutaneous Coronary Intervention for Patients With Stable Ischemic Heart Disease. <i>JAMA Internal Medicine</i> , 2016, 176, 1190.	5.1	10
50	Impact of revascularisation on outcomes in chronic coronary syndromes: a new meta-analysis with the same old biases?. <i>European Heart Journal</i> , 2021, 42, 4652-4655.	2.2	10
51	Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management. <i>JAMA Cardiology</i> , 2021, 6, 1023.	6.1	10
52	What constitutes an appropriate empirical trial of antianginal therapy in patients with stable angina before referral for revascularisation?. <i>Lancet</i> , The, 2022, 399, 691-694.	13.7	10
53	Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2013, 111, 439-444.	1.6	9
54	Is HPS2-THRIVE the death knell for niacin?. <i>Journal of Clinical Lipidology</i> , 2015, 9, 343-350.	1.5	9

#	ARTICLE	IF	CITATIONS
55	Pragmatic, adaptive clinical trials: Is 2020 the dawning of a new age?. Contemporary Clinical Trials Communications, 2020, 19, 100614.	1.1	9
56	Cost-effectiveness analysis of percutaneous coronary intervention for single-vessel coronary artery disease: an economic evaluation of the ORBITA trial. BMJ Open, 2021, 11, e044054.	1.9	9
57	OUP accepted manuscript. European Heart Journal, 2021, , .	2.2	9
58	CABG for Complex CAD: When Will Evidence-Based Practice Align With Evidence-Based Medicine?—. Journal of the American College of Cardiology, 2016, 67, 56-58.	2.8	8
59	Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the <scp>TRILOGY ACS</scp> Trial. Clinical Cardiology, 2016, 39, 329-337.	1.8	7
60	Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT. Journal of Clinical Lipidology, 2022, 16, 389-402.	1.5	7
61	Predictors of Initial Revascularization Versus Medical Therapy Alone in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing an Invasive Strategy. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	6
62	Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trial. Journal of Clinical Lipidology, 2018, 12, 741-747.e11.	1.5	6
63	Conservative versus invasive stable ischemic heart disease management strategies: what do we plan to learn from the ISCHEMIA trial?. Future Cardiology, 2016, 12, 35-44.	1.2	5
64	Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?. Circulation, 2018, 138, 858-860.	1.6	5
65	Does Physiology Trump Anatomy as the “Best Course” to Guide PCI Decision Making and Outcomes? —. Journal of the American College of Cardiology, 2016, 67, 1712-1714.	2.8	4
66	Diagnostic Implications in the Aftermath of the ISCHEMIA Trial. American Journal of Cardiology, 2020, 125, 1438-1440.	1.6	4
67	Defining the Proper SYNTAX for Long-Term Benefit of Myocardial Revascularization With Optimal Medical Therapy. Journal of the American College of Cardiology, 2021, 78, 39-41.	2.8	4
68	Is there equivalence between PCI and CABG surgery in long-term survival of patients with diabetes? Importance of interpretation biases and biological plausibility. European Heart Journal, 2021, 43, 68-70.	2.2	4
69	Evaluation of the stable coronary artery disease patient: Anatomy trumps physiology. Trends in Cardiovascular Medicine, 2014, 24, 332-340.	4.9	3
70	Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. Heart, 2016, 102, 1221-1229.	2.9	3
71	Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial. American Heart Journal, 2016, 178, 55-64.	2.7	3
72	Reconsidering the Gatekeeper Paradigm for Percutaneous Coronary Intervention in Stable Coronary Disease Management. American Journal of Cardiology, 2017, 120, 1450-1452.	1.6	3

#	ARTICLE	IF	CITATIONS
73	Meta-Analysis of the Effect of Percutaneous Coronary Intervention on Death and Myocardial Infarction in Patients With Stable Coronary Artery Disease and Inducible Myocardial Ischemia. American Journal of Cardiology, 2020, 133, 171-174.	1.6	3
74	PCSK9 Inhibition for Therapeutic Decision-Making. Journal of the American College of Cardiology, 2020, 75, 2309-2311.	2.8	3
75	To stent or not to stent? Treating angina after ISCHEMIA—introduction. European Heart Journal, 2021, 42, 1387-1400.	2.2	3
76	To stent or not to stent? Treating angina after ISCHEMIA—why a conservative approach with optimal medical therapy is the preferred initial management strategy for chronic coronary syndromes: insights from the ISCHEMIA trial. European Heart Journal, 2021, 42, 1394-1400.	2.2	3
77	Translating the findings of ISCHEMIA into clinical practice: a challenging START. EuroIntervention, 2020, 16, e953-e956.	3.2	3
78	Optimizing Dyslipidemic Cardiovascular Residual Risk Reduction With Icosapent Ethyl in Post-MI Patients. Journal of the American College of Cardiology, 2022, 79, 1672-1674.	2.8	3
79	Role of Dual Antiplatelet Therapy in Symptomatic Patients with Established Vascular Disease: Putting the CHARISMA Trial into Therapeutic Perspective. Cardiovascular Drugs and Therapy, 2010, 24, 207-216.	2.6	2
80	Why Optimal Medical Therapy Should Be a Universal Standard of Care —. Journal of the American College of Cardiology, 2015, 66, 774-776.	2.8	2
81	Revascularization options in stable coronary artery disease: it is not how to revascularize, it is whether and when to revascularize. Journal of Comparative Effectiveness Research, 2015, 4, 505-514.	1.4	2
82	Effect of Baseline Exercise Capacity on Outcomes in Patients With Stable Coronary Heart Disease (A) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	2
83	A PROMISE Fulfilled That Quality-of-Life Assessments Afford Incremental Value to Coronary Artery Disease Management. Circulation, 2016, 133, 1989-1991.	1.6	2
84	Role of Imaging in the Management of Stable Ischemic Heart Disease. JACC: Cardiovascular Imaging, 2017, 10, 335-337.	5.3	2
85	Risk Prediction Tool for Assessing the Probability of Death or Myocardial Infarction in Patients With Stable Coronary Artery Disease. American Journal of Cardiology, 2020, 130, 1-6.	1.6	2
86	The nomenclature vagaries for the clinical manifestations of myocardial ischemic syndromes — A call to action. International Journal of Cardiology, 2020, 304, 5-7.	1.7	2
87	The Rising Urgency to Pivot Back Toward Hippocratic Medicine. American Journal of Medicine, 2022, 135, 49-52.	1.5	2
88	As REGARDS Treatment Goal Attainment Compared With COURAGE. Journal of the American College of Cardiology, 2014, 63, 1634-1635.	2.8	1
89	A Novel Diagnostic Approach for Evaluating Suspected Coronary Artery Disease. American Journal of Medicine, 2016, 129, 557-559.	1.5	1
90	Role of Ranolazine in Reducing Angina, Subsequent Revascularization, and Healthcare Expenditures in Stable Ischemic Heart Disease. American Journal of Cardiology, 2019, 123, 1729-1731.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Deferral of PCI, a safe strategy in diabetic patients with chronic coronary syndromes. Heart, 2020, 106, 1627-1628.	2.9	1
92	Will REFINe Resurrect the "Ischemia Hypothesis"? JACC: Cardiovascular Imaging, 2021, 14, 654-656.	5.3	1
93	Interpreting the results of the COURAGE trial: a non-interventionalist perspective. Reviews in Cardiovascular Medicine, 2009, 10 Suppl 2, S34-44.	1.4	1
94	The continued importance of optimal medical therapy with or without revascularization in diabetic patients with coronary artery disease. Trends in Cardiovascular Medicine, 2015, 25, 632-634.	4.9	0
95	MY APPROACH to managing stable ischemic heart disease. Trends in Cardiovascular Medicine, 2015, 25, 753-754.	4.9	0
96	Should Beta-Blockers Continue to Be Used in Post-Percutaneous Coronary Intervention Patients Without Myocardial Infarction? JACC: Cardiovascular Interventions, 2016, 9, 1649-1651.	2.9	0
97	Successful percutaneous coronary intervention significantly improves coronary sinus blood flow as assessed by transthoracic echocardiography. Journal of Echocardiography, 2018, 16, 65-71.	0.8	0
98	Evolving from volume to value, or to a bolder vision of reimbursement reform? American Heart Journal, 2018, 204, 174-177.	2.7	0
99	Letter by Boden Regarding Article, "Effects of Percutaneous Coronary Intervention on Death and Myocardial Infarction Stratified by Stable and Unstable Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials," Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006632.	2.2	0
100	RESPONSE: The Exit Interview of a Professional Lifetime. Journal of the American College of Cardiology, 2021, 77, 2256-2257.	2.8	0
101	The sounds of silence. European Heart Journal, 0, , .	2.2	0
102	Evolving Roles of Optimal Medical Therapy and PCI in Chronic Coronary Syndrome Patients with Stable Angina: Introduction. Cardiovascular Drugs and Therapy, 0, , .	2.6	0